Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Indaptus Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 18 | 15 | −3 |
| Shares | 576.6K | 579.3K | +2.78K (+0.5%) |
| Value | $838.5K | $1.08M | +$240.9K (+28.7%) |
New holders (1)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pine Valley Investments Ltd Liability Co | 44,420 | $89.7K | 0.01% |
Sold out (4)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Stratos Wealth Partners, LTD. | 26,832 | $38.9K |
| Susquehanna International Group, LLP | 14,495 | $20.9K |
| Bank of America Corp | 11 | $16 |
| Harel Insurance Investments & Financial Services Ltd. | 117 | $0 |